Locomotion Adaptation Deficits in Older Adults With Mild Cognitive Impairment and Alzheimers Disease (NCT06484244)
🩺 Plain-English Summary (8th-Grade Level)
In people with Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD), reduced capacity for locomotor adaptation is a fundamental but poorly understood mechanism that can be a sensitive biomarker of cognitive-motor impairments. It is also an important therapeutic target for exercise-based interventions to improve walking function. The overall goal of this study is to understand the effects of MCI and AD on locomotor adaptation and walking function.
Who can join: Review the eligibility criteria below.
Location: Emory Rehabilitation Hospital — Atlanta, Georgia
Age range: 50 Years to 90 Years
🧪 Interventions in This Study
- 5 Sessions of Split-belt Treadmill-based Locomotor Adaptation (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Emory Rehabilitation Hospital — Atlanta, Georgia
📞 Contact the Study Coordinator
Phone: (404) 712-5803
Email: tkesar@emory.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Alzheimers Disease
- Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) — Birmingham, Alabama
- Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease — Atlantis, Florida
- Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 — Birmingham, Alabama
- A Post Authorization Registry Study of Participants Treated With LEQEMBI — Vancouver, British Columbia
- A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease — Phoenix, Arizona
- A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation — Birmingham, Alabama
Explore by condition: All Alzheimers Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.